JP2023539047A5 - - Google Patents

Info

Publication number
JP2023539047A5
JP2023539047A5 JP2023509698A JP2023509698A JP2023539047A5 JP 2023539047 A5 JP2023539047 A5 JP 2023539047A5 JP 2023509698 A JP2023509698 A JP 2023509698A JP 2023509698 A JP2023509698 A JP 2023509698A JP 2023539047 A5 JP2023539047 A5 JP 2023539047A5
Authority
JP
Japan
Prior art keywords
patients
patients weighing
day
composition according
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023509698A
Other languages
English (en)
Japanese (ja)
Other versions
JP7821160B2 (ja
JP2023539047A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/045823 external-priority patent/WO2022036151A1/en
Publication of JP2023539047A publication Critical patent/JP2023539047A/ja
Publication of JP2023539047A5 publication Critical patent/JP2023539047A5/ja
Priority to JP2025204019A priority Critical patent/JP2026026191A/ja
Application granted granted Critical
Publication of JP7821160B2 publication Critical patent/JP7821160B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023509698A 2020-08-13 2021-08-12 造血幹細胞移植関連血栓性微小血管症(hsct-tma)を処置するための抗c5抗体の用量及び投与 Active JP7821160B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025204019A JP2026026191A (ja) 2020-08-13 2025-11-26 造血幹細胞移植関連血栓性微小血管症(hsct-tma)を処置するための抗c5抗体の用量及び投与

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063065107P 2020-08-13 2020-08-13
US63/065,107 2020-08-13
PCT/US2021/045823 WO2022036151A1 (en) 2020-08-13 2021-08-12 Dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025204019A Division JP2026026191A (ja) 2020-08-13 2025-11-26 造血幹細胞移植関連血栓性微小血管症(hsct-tma)を処置するための抗c5抗体の用量及び投与

Publications (3)

Publication Number Publication Date
JP2023539047A JP2023539047A (ja) 2023-09-13
JP2023539047A5 true JP2023539047A5 (cg-RX-API-DMAC7.html) 2024-08-22
JP7821160B2 JP7821160B2 (ja) 2026-02-26

Family

ID=77655658

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023509698A Active JP7821160B2 (ja) 2020-08-13 2021-08-12 造血幹細胞移植関連血栓性微小血管症(hsct-tma)を処置するための抗c5抗体の用量及び投与
JP2025204019A Pending JP2026026191A (ja) 2020-08-13 2025-11-26 造血幹細胞移植関連血栓性微小血管症(hsct-tma)を処置するための抗c5抗体の用量及び投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025204019A Pending JP2026026191A (ja) 2020-08-13 2025-11-26 造血幹細胞移植関連血栓性微小血管症(hsct-tma)を処置するための抗c5抗体の用量及び投与

Country Status (10)

Country Link
US (1) US20240209071A1 (cg-RX-API-DMAC7.html)
EP (1) EP4196161A1 (cg-RX-API-DMAC7.html)
JP (2) JP7821160B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230047179A (cg-RX-API-DMAC7.html)
CN (1) CN116249550A (cg-RX-API-DMAC7.html)
AU (2) AU2021326526B2 (cg-RX-API-DMAC7.html)
CA (1) CA3173007A1 (cg-RX-API-DMAC7.html)
IL (1) IL300115A (cg-RX-API-DMAC7.html)
MX (1) MX2023001702A (cg-RX-API-DMAC7.html)
WO (1) WO2022036151A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202426048A (zh) 2022-09-06 2024-07-01 美商阿雷希昂製藥公司 用於治療造血幹細胞移植相關血栓性(hsct-tma)的抗c5抗體的補充劑量和投與
CA3266977A1 (en) 2022-09-06 2024-03-14 Alexion Pharmaceuticals, Inc. DIAGNOSTIC AND PROGNOSIS BIOMARKER PROFILES IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
ES2796078T3 (es) * 2013-09-16 2020-11-25 Childrens Hospital Med Ct Composiciones y métodos para el tratamiento de la microangiopatía trombótica asociada al hsct
NZ711451A (en) * 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
CA3024618A1 (en) * 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
JP7518764B2 (ja) * 2017-10-26 2024-07-18 アレクシオン ファーマシューティカルズ, インコーポレイテッド 発作性夜間ヘモグロビン尿症(PNH)および非典型溶血性尿毒症症候群(aHUS)の処置のための抗C5抗体の投薬量および投与
EP3802603A1 (en) * 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
US20230416344A1 (en) * 2020-04-16 2023-12-28 Alexion Pharmaceuticals, Inc. Methods for treating a complement mediated disorder caused by viruses

Similar Documents

Publication Publication Date Title
AU2022202649B2 (en) Antibody formulations and methods
JP7101621B2 (ja) 単一ドメイン血清アルブミン結合タンパク質
JP2021501134A5 (cg-RX-API-DMAC7.html)
JP2021526534A5 (cg-RX-API-DMAC7.html)
JP2021525718A5 (cg-RX-API-DMAC7.html)
US9243060B2 (en) Humanized anti-factor C3b antibodies and uses thereof
JP2026053516A (ja) バイオ医薬組成物
JP2023533030A5 (cg-RX-API-DMAC7.html)
DK166763B1 (da) Immunoglobulin-g-holdig fraktion
JP2019507107A (ja) 抗N3pGluアミロイドベータペプチド抗体及びその使用
JP6105146B2 (ja) Pan−ELR+CXCケモカイン抗体
JP7788281B2 (ja) 可溶性補体受容体1型変異体コンジュゲートおよびその使用
EA014025B1 (ru) Композиции антитела против cd3
EP4501965A1 (en) Antibody, fusion protein and use thereof
JP2024540480A5 (cg-RX-API-DMAC7.html)
CN115768789A (zh) 用于获得包含人血浆来源的免疫球蛋白m的组合物的方法
KR20110128271A (ko) Abo식 혈액형과 관련한 모-태아 간 부적합에 의해 야기된 신생아 황달 치료용 항-a 및 항-b가 대폭 감소된 면역 글로불린 g(면역 글로불린 g) 농축물의 용도
US20230173155A1 (en) Dialysis system for treating sepsis
JP4339405B2 (ja) 予防・治療剤
Kato et al. Rapid deterioration of the renal function caused by the coexistence of intratubular amyloidosis and myeloma cast nephropathy
JP6942356B2 (ja) 制御性t細胞の活性化剤及びその使用
KR20230142834A (ko) 항-cd38 항체 및 이의 용도
JP2025529317A5 (cg-RX-API-DMAC7.html)
CN111704670B (zh) 重组抗RANKL抗体IgG2型的二硫键异构体及其纯化方法
JPH0585529B2 (cg-RX-API-DMAC7.html)